RedHill Biopharma Ltd. (RDHL)

RedHill Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	6.36	35.97	29.47	29.3	29.02
Short-Term Investments	0	0.02	8.53	0.5	18.85
Cash & Cash Equivalents	6.36	35.98	38	29.79	47.87
Cash Growth	-82.33%	-5.32%	27.56%	-37.77%	-9.99%
Receivables	2.59	34.52	31.68	28.66	1.22
Inventory	4.39	11.01	14.81	6.53	1.88
Other Current Assets	2.8	4.39	4.66	5.52	2.24
Total Current Assets	16.14	85.9	89.15	70.5	53.21
Property, Plant & Equipment	1.18	7.19	4.22	5.7	3.81
Long-Term Investments	0.15	0.15	16.17	16.16	0.15
Goodwill and Intangibles	5.58	65.63	71.64	87.88	16.93
Total Long-Term Assets	6.91	72.97	92.04	109.75	20.89
Total Assets	23.05	158.87	181.19	180.24	74.1
Accounts Payable	3.28	4.23	11.66	11.55	4.18
Current Debt	0.72	116.25	1.62	1.71	0.83
Other Current Liabilities	15.25	76.98	68.19	59.97	5.6
Total Current Liabilities	19.24	197.45	81.47	73.24	10.62
Long-Term Debt	0.46	6.44	86.19	85.19	2.98
Other Long-Term Liabilities	1.28	3.37	4.65	7.95	0.5
Total Long-Term Liabilities	1.74	9.82	90.84	93.14	3.48
Total Liabilities	20.98	207.27	172.31	166.38	14.1
Total Debt	1.17	122.69	87.81	86.9	3.82
Debt Growth	-99.04%	39.72%	1.05%	2177.93%	-
Retained Earnings	-407.74	-433.86	-367.87	-280.33	-208.36
Shareholders' Equity	2.07	-48.4	8.88	13.86	60
Net Cash / Debt	5.19	-86.71	-49.81	-57.11	44.06
Net Cash / Debt Growth	-	-	-	-	-17.16%
Working Capital	-3.1	-111.55	7.68	-2.74	42.6
Book Value Per Share	0.65	-30.33	7.59	15.72	84.60

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).